Table 3 Shows the enhancement role of Fagonia cretica extract (FCE) on Bisphenol A-induced chromosomal aberrations in rats

Normal control

1.0 ± 0.32^d

0.40 ± 0.24^f

0.40 ± 0.25^d

0.60 ± 0.40^e

0.20 ± 0.20^d

2.60 ± 0.81^f

0.60 ± 0.25^d

3.20 ± 0.80^f

Control oil treatment

1.20 ± 0.37^d

0.80 ± 0.37^ef

0.40 ± 0.25^d

1.0 ± 0.45^e

0.60 ± 0.25^cd

4.0 ± 0.44^f

0.60 ± 0.25^d

4.60 ± 0.51^f

Bisphenol A (BPA)

5.40 ± 0.75^a

3.60 ± 0.51^a

4.80 ± 0.74^a

7.20 ± 0.37^a

3.0 ± 0.32^a

24.0 ± 1.22^a

5.40 ± 0.68^a

29.40 ± 0.68^a

Protective low dose of FCE

2.80 ± 0.37^c

2.20 ± 0.20^bcd

1.40 ± 0.40^cd

5.40 ± 0.51^b

2.20 ± 0.49^ab

14.0 ± 0.63^cd

3.40 ± 0.40^b

17.40 ± 0.51^c

Protective medium dose of FCE

2.80 ± 0.20^c

1.80 ± 0.37^cde

1.40 ± 0.25^cd

4.40 ± 0.40^bc

2.0 ± 0.32^ab

12.0 ± 0.63^d

2.40 ± 0.51^bc

14.40 ± 0.81^d

Protective high dose of FCE

2.0 ± 0.32 ^cd

1.20 ± 0.37^def

1.0 ± 0.32^cd

2.40 ± 0.51^d

1.60 ± 0.51^bc

8.60 ± 0.87^e

1.80 ± 0.37^cd

10.40 ± 1.0^e

Therapeutic low dose of FCE

5.0 ± 0.32^ab

3.0 ± 0.45^ab

4.20 ± 0.37^ab

3.40 ± 0.40^cd

2.40 ± 0.51^ab

18.0 ± 1.18^b

5.20 ± 0.66^a

23.20 ± 0.86^b

Therapeutic medium dose of FCE

4.0 ± 0.32^b

2.60 ± 0.26^abc

3.20 ± 0.20^b

3.0 ± 0.55^d

3.0 ± 0.32^a

15.60 ± 0.75^bc

3.60 ± 0.51^b

18.80 ± 0.86^c

Therapeutic high dose of FCE

2.20 ± 0.37 ^cd

2.20 ± 0.37^bcd

2.0 ± 0.32^c

2.60 ± 0.40^d

2.80 ± 0.20^a

11.80 ± 1.0^d

2.60 ± 0.51^bc

14.40 ± 0.41^d